# Debate Matchup Judgment Report

**Claude Sonnet 4.6 (high)** vs **Kimi K2.6**

- Paired result: **Claude Sonnet 4.6 (high)**
- Mean entertainment: `8.00 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Clinical trials should be required to include proportionate representation across age, sex, and ethnic groups even if that materially slows drug approvals.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0191__claude-sonnet-4-6-adaptive__kimi-k2.6__s0__tpl_placement_active_20260320f.md): PRO = **Claude Sonnet 4.6 (high)**, CON = **Kimi K2.6**
- [Debate B transcript](../../../transcripts/prop_0191__kimi-k2.6__claude-sonnet-4-6-adaptive__s1__tpl_placement_active_20260320f.md): PRO = **Kimi K2.6**, CON = **Claude Sonnet 4.6 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_20260814a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0191__claude-sonnet-4-6-adaptive__kimi-k2.6__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **Claude Sonnet 4.6 (high)**, CON = **Kimi K2.6**
- Judged result: Unanimous `3-0` for **Claude Sonnet 4.6 (high)**.
- Entertainment scores: `8`, `8`, `8`
- Mean signed raw margin (PRO+): `+1.63`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| GPT-5.5 (high) | A = Kimi K2.6 (CON); B = Claude Sonnet 4.6 (high) (PRO) | Claude Sonnet 4.6 (high) | +1.6 | +1.71 | 8.0 |
| Gemini 3.1 Pro Preview | A = Kimi K2.6 (CON); B = Claude Sonnet 4.6 (high) (PRO) | Claude Sonnet 4.6 (high) | +1.8 | +1.50 | 8.0 |
| Qwen 3.6 Max Preview | A = Claude Sonnet 4.6 (high) (PRO); B = Kimi K2.6 (CON) | Claude Sonnet 4.6 (high) | +1.5 | +1.50 | 8.0 |

### Judge Notes

- **GPT-5.5 (high)** (A = Kimi K2.6 (CON); B = Claude Sonnet 4.6 (high) (PRO)): Side B wins because it made the central weighing clearer: delay harms are real, but so are the systematic harms caused by approving drugs on evidence that excludes likely users. Side A’s strongest route was immediate mortality from delay, but it overstated this as certain and repeatedly attacked “census quotas” after Side B plausibly defined proportionate representation as matching the treated patient population. Side B also turned Side A’s reliance on post-market surveillance by arguing that if follow-up is unreliable, pre-approval is the enforceable checkpoint. Side A remained competitive with the point that trials cannot eliminate all uncertainty and delays can be deadly, but it too often framed B as demanding perfect certainty rather than better pre-approval evidence.
  Most decisive rebuttal noted: Side B’s most decisive exchange was answering the post-market surveillance argument: Side A admitted follow-up often fails, which let Side B argue that excluded patients bear the cost unless representation is required before approval.
- **Gemini 3.1 Pro Preview** (A = Kimi K2.6 (CON); B = Claude Sonnet 4.6 (high) (PRO)): Side B won by successfully reframing Side A's "certain vs. probabilistic" impact weighing as a bookkeeping bias that ignores deferred harm. Side B also decisively won the policy mechanism clash by proving that if post-market surveillance consistently fails, pre-approval is the only reliable checkpoint.
  Most decisive rebuttal noted: Side B's closing crystallization that Side A's reliance on "administrative failure" to explain persistent gaps makes pre-approval the only reliable enforcement mechanism, turning Side A's own systemic skepticism against them.
- **Qwen 3.6 Max Preview** (A = Claude Sonnet 4.6 (high) (PRO); B = Kimi K2.6 (CON)): Side A wins by successfully controlling the definition of "proportionate representation" to mean the target patient population rather than general census mirroring, which neutralized Side B's strongest practical examples (sickle-cell, pediatric trials). More decisively, Side A turned Side B's concession about systemic administrative failure into a winning argument: if post-market follow-up routinely fails, pre-approval mandates are the only enforceable checkpoint. Side A's "bookkeeping bias" frame effectively exposed Side B's one-dimensional weighing of immediate delay deaths over systematic, compounding harm. Side B delivered strong rhetoric on the certainty of delay but never adequately resolved why invisible harm should be discounted or how a broken system would reliably manage post-market risks.
  Most decisive rebuttal noted: Side A's Rebuttal 2 and Closing, where they directly answer Side B's pressure questions and pivot Side B's "administrative negligence" argument against them. By arguing that regulatory failure makes pre-approval mandates more necessary, not less, Side A collapses Side B's post-market safety net and forces a clean comparison on enforceable evidence standards versus deferred harm.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0191__kimi-k2.6__claude-sonnet-4-6-adaptive__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **Kimi K2.6**, CON = **Claude Sonnet 4.6 (high)**
- Judged result: Split `2-1` for **Claude Sonnet 4.6 (high)**.
- Entertainment scores: `8`, `8`, `8`
- Mean signed raw margin (PRO+): `-0.83`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| GPT-5.5 (high) | A = Claude Sonnet 4.6 (high) (CON); B = Kimi K2.6 (PRO) | Kimi K2.6 | +0.8 | +0.86 | 8.0 |
| Gemini 3.1 Pro Preview | A = Claude Sonnet 4.6 (high) (CON); B = Kimi K2.6 (PRO) | Claude Sonnet 4.6 (high) | -1.8 | -1.50 | 8.0 |
| Qwen 3.6 Max Preview | A = Kimi K2.6 (PRO); B = Claude Sonnet 4.6 (high) (CON) | Claude Sonnet 4.6 (high) | -1.5 | -1.50 | 8.0 |

### Judge Notes

- **GPT-5.5 (high)** (A = Claude Sonnet 4.6 (high) (CON); B = Kimi K2.6 (PRO)): B narrowly won by making the central tradeoff about pre-market validity and leverage rather than mere diversity symbolism. A’s statistical-power critique and delay framing were strong, but B reasonably answered that proportional representation is a floor that creates usable baseline safety and tolerability evidence, not a promise of definitive subgroup trials. B also did more damage to A’s alternatives by arguing that post-market surveillance exposes patients first and loses leverage once approval and revenue arrive. A’s closing was sharper on the “weak signal for material delay” point, but it over-demanded definitive subgroup proof and never fully showed that its alternatives protect excluded groups before exposure.
  Most decisive rebuttal noted: B’s answer to the alternatives was the key exchange: post-market surveillance and parallel studies were framed as discovering demographic risk only after approval, while mandatory representation uses the approval gate as leverage.
- **Gemini 3.1 Pro Preview** (A = Claude Sonnet 4.6 (high) (CON); B = Kimi K2.6 (PRO)): Side A won by exploiting a core statistical flaw in the proposition: proportionate representation mathematically fails to properly power minority subgroup analyses. When Side B conceded that the mandate might only yield weak signals like 'pharmacokinetic baselines,' Side A decisively crystallized the clash, demonstrating that Side B was trading deadly material delays for incomplete data.
  Most decisive rebuttal noted: Side A's second rebuttal brilliantly weaponized Side B's concession about 'pharmacokinetic baselines' to prove the mandate only purchases a weak signal at the full price of material delay.
- **Qwen 3.6 Max Preview** (A = Kimi K2.6 (PRO); B = Claude Sonnet 4.6 (high) (CON)): CON wins by successfully exploiting PRO's concession that proportionate enrollment rarely powers definitive subgroup analyses, reframing the mandate as purchasing weak signal at the cost of certain, material delay. While PRO effectively argued that pre-approval is the only real leverage against sponsor resistance, CON neutralized this by demonstrating that leverage is practically worthless if the scientific output remains statistically inadequate for the granular safety questions the motion aims to solve. CON also maintained consistently sharper weighing on the explicit delay cost baked into the proposition, whereas PRO repeatedly dodged balancing delay-deaths against demographic harms. CON's closing crystallized this tradeoff decisively and cleanly resolved the central clash.
  Most decisive rebuttal noted: CON's Rebuttal 2 and Closing effectively turned PRO's core leverage argument by asserting that leverage purchasing incomplete science is not worth the lethal cost of delay, encapsulating the decisive comparison in the sharp framing: the mandate delivers the appearance of rigor at full price, while targeted alternatives yield properly powered data without holding approvals hostage.

## Technical metadata

- Evaluation scope: `judge_judge_blend_20260814a__debate_all_templates`
- Topic ID: `prop_0191`
- Side-swap group ID: `prop_0191__claude-sonnet-4-6-adaptive__kimi-k2.6__tpl_placement_active_20260320f`
- Raw paired winner: **Claude Sonnet 4.6 (high)**
- Mean normalized margin for Claude Sonnet 4.6 (high): `+1.14`
- Complete side swap: `yes`
- Included in ratings: `yes`
